WO1999020291A3 - Pharmaceutical grade ginkgo biloba - Google Patents

Pharmaceutical grade ginkgo biloba Download PDF

Info

Publication number
WO1999020291A3
WO1999020291A3 PCT/US1998/022506 US9822506W WO9920291A3 WO 1999020291 A3 WO1999020291 A3 WO 1999020291A3 US 9822506 W US9822506 W US 9822506W WO 9920291 A3 WO9920291 A3 WO 9920291A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical grade
materials
ginkgo biloba
ginkgo
present
Prior art date
Application number
PCT/US1998/022506
Other languages
French (fr)
Other versions
WO1999020291A9 (en
WO1999020291A2 (en
Inventor
Tasneem A Khwaja
Elliot P Friedman
Original Assignee
Pharmaprint Inc
Univ Southern California
Tasneem A Khwaja
Elliot P Friedman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaprint Inc, Univ Southern California, Tasneem A Khwaja, Elliot P Friedman filed Critical Pharmaprint Inc
Priority to AU13633/99A priority Critical patent/AU1363399A/en
Priority to JP2000516688A priority patent/JP2002515402A/en
Priority to CA002307194A priority patent/CA2307194A1/en
Priority to EP98957357A priority patent/EP1027603A2/en
Publication of WO1999020291A2 publication Critical patent/WO1999020291A2/en
Publication of WO1999020291A3 publication Critical patent/WO1999020291A3/en
Publication of WO1999020291A9 publication Critical patent/WO1999020291A9/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates generally to ginkgo materials and methods for making such materials in medicinally useful and pharmaceutically acceptable forms. More particularly, the present invention relates to the use of compositional and activity fingerprints in the processing of ginkgo materials to produce drugs which qualify as pharmaceutical grade compositions which are suitable for use in clinical or veterinary settings to treat and/or ameliorate diseases, disorders or conditions.
PCT/US1998/022506 1997-10-23 1998-10-23 Pharmaceutical grade ginkgo biloba WO1999020291A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU13633/99A AU1363399A (en) 1997-10-23 1998-10-23 Pharmaceutical grade ginkgo biloba
JP2000516688A JP2002515402A (en) 1997-10-23 1998-10-23 Pharmaceutical grade ginkgo
CA002307194A CA2307194A1 (en) 1997-10-23 1998-10-23 Pharmaceutical grade ginkgo biloba
EP98957357A EP1027603A2 (en) 1997-10-23 1998-10-23 Pharmaceutical grade ginkgo biloba

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95660097A 1997-10-23 1997-10-23
US08/956,600 1997-10-23

Publications (3)

Publication Number Publication Date
WO1999020291A2 WO1999020291A2 (en) 1999-04-29
WO1999020291A3 true WO1999020291A3 (en) 1999-07-08
WO1999020291A9 WO1999020291A9 (en) 1999-08-12

Family

ID=25498427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022506 WO1999020291A2 (en) 1997-10-23 1998-10-23 Pharmaceutical grade ginkgo biloba

Country Status (6)

Country Link
EP (1) EP1027603A2 (en)
JP (1) JP2002515402A (en)
CN (1) CN1290349A (en)
AU (1) AU1363399A (en)
CA (1) CA2307194A1 (en)
WO (1) WO1999020291A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1009437C2 (en) * 1998-06-18 1999-12-21 Xenobiosis Extraction process.
US20030044846A1 (en) 2001-04-03 2003-03-06 Gary Eldridge Screening of chemical compounds purified from biological sources
WO2001033193A2 (en) * 1999-11-02 2001-05-10 Sequoia Sciences, Inc. Automated plant extraction method and arrays for high throughput screening
JP2007246507A (en) * 2006-02-15 2007-09-27 Kracie Seiyaku Kk Prophylactic or curative composition for fatigue and method for preventing or treating fatigue
CN110433157B (en) * 2018-05-02 2022-10-18 成都百裕制药股份有限公司 Application of ginkgolide in preparation of medicine for preventing and/or treating vertigo
CN109053417B (en) * 2018-07-27 2021-03-05 山东省分析测试中心 Preparation method of high-purity ginkgolic acid
CN117024440A (en) * 2021-03-30 2023-11-10 成都百裕制药股份有限公司 Terpene lactone derivative and application thereof in medicine
CN113533270A (en) * 2021-06-16 2021-10-22 万邦德制药集团有限公司 Quality control method of ginkgo leaf dripping pills
CN117815223B (en) * 2024-03-06 2024-07-30 北京市肿瘤防治研究所 Application of ginkgo biflavone in preparing medicine for resisting esophageal squamous carcinoma

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431535A1 (en) * 1989-12-04 1991-06-12 Dr. Willmar Schwabe GmbH & Co. Extract from Ginkgo biloba leaves, its method of preparation and pharmaceuticals containing the extract
WO1996032122A1 (en) * 1995-04-14 1996-10-17 University Of Southern California Mistletoe extract and method
WO1997039355A1 (en) * 1996-04-15 1997-10-23 Pharmaprint, Inc. Pharmaceutical grade botanical drugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431535A1 (en) * 1989-12-04 1991-06-12 Dr. Willmar Schwabe GmbH & Co. Extract from Ginkgo biloba leaves, its method of preparation and pharmaceuticals containing the extract
WO1996032122A1 (en) * 1995-04-14 1996-10-17 University Of Southern California Mistletoe extract and method
WO1997039355A1 (en) * 1996-04-15 1997-10-23 Pharmaprint, Inc. Pharmaceutical grade botanical drugs

Also Published As

Publication number Publication date
JP2002515402A (en) 2002-05-28
WO1999020291A9 (en) 1999-08-12
WO1999020291A2 (en) 1999-04-29
CN1290349A (en) 2001-04-04
CA2307194A1 (en) 1999-04-29
EP1027603A2 (en) 2000-08-16
AU1363399A (en) 1999-05-10

Similar Documents

Publication Publication Date Title
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
SI0751129T1 (en) Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
ZA975866B (en) Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases.
HUP9700603A3 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MA26536A1 (en) COMBINATION OF PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN AND ANTIHYPERTENSITIVE AGENTS, AND PROCESS FOR THEIR PREPARATION.
MXPA02003596A (en) Novel pharmaceutical compositions of anti-tubercular drugs and process for their preparation.
WO2001041762A3 (en) Valdecoxib compositions
MA26420A1 (en) MIXED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOPOROSIS, AND METHOD FOR THEIR PREPARATION.
IL127943A (en) Pharmaceutical and cosmetic compositions for the treatment of skin disorders
HUP9803018A3 (en) Use of cyclooxygenase-2 inhibitors for producing pharmaceutical compositions suitable for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
HUP0200284A2 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2001001974A3 (en) Naaladase inhibitors in anxiety and memory disorders
ZA98960B (en) Pharmaceutical composition for treatment of synaptic dysfunction and related disease disorders
WO1999020291A3 (en) Pharmaceutical grade ginkgo biloba
EE03663B1 (en) Method of preventing breast cancer, pharmaceutical preparation and product, and use of the active ingredient
HUP0002346A1 (en) Pharmaceutical composition for the treatment of mental illness in mammals
HUP0401325A3 (en) Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds
AU1546101A (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
DE69939075D1 (en) Pharmaceutical composition for the prevention and treatment of diseases associated with cell diseases of the fundus

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98812473.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/4-4/4, DRAWINGS, REPLACED BY NEW PAGES 1/4-4/4; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 09331827

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2307194

Country of ref document: CA

Ref document number: 2307194

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998957357

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2000 516688

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 13633/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998957357

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998957357

Country of ref document: EP